Desmoglein-2 modulates tumor progression and osimertinib drug resistance through the EGFR/Src/PAK1 pathway in lung adenocarcinoma

Publisher Website
Google Scholar
Abstract
No abstract available
Funding Information
  • National Natural Science Foundation of China (81802299, 81502514, 81702841)
  • Fundamental Research Funds for the Central Universities (3332018070)
  • CAMS Innovation Fund for Medical Sciences (2016-I2M-1-001, 2017-I2M-1-005),)
  • the National Key Basic Research Development Plan (2018YFC1312105)
  • Shanghai Municipal Commission of Health and Family Planning Young Scientists Fund (20164Y0253)
  • China Postdoctoral Science Foundation (2019M650568)